Successful treatment of abnormal sensation associated with restless legs syndrome in adrenoleukodystrophy using Gunggwijohyeoleum-Jeilgagam: A case report.

Explore (NY)Jun 1, 2026 (epub)
Case ReportNeurologyPsychiatry

Sunghee Hong, Han-Gyul Lee, Seungwon Kwon et al.

✦ AI-curated · Sources linked

Case in brief

A 50-year-old man with adrenoleukodystrophy (ALD) and a 10-year history of refractory restless legs syndrome (RLS) presented with severe symptoms, including insomnia and gait impairment. Conventional treatments were ineffective. After 21 days of treatment with the herbal medicine Gunggwijohyeoleum-Jeilgagam, his RLS symptoms significantly improved, with a reduction in the International Restless Legs Syndrome Rating Scale score and increased sleep duration, effects lasting for 5 months post-treatment.

Diagnostic / clinical pearl

This case highlights the potential of herbal medicine as a complementary treatment for refractory restless legs syndrome in patients with neurodegenerative disorders when conventional therapies fail.

Source

PubMed · PMID 42251809

Published in Explore (NY). This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.